293 related articles for article (PubMed ID: 9638854)
1. A randomized prospective study comparing low-dose OKT3 to low-dose ATG for the treatment of acute steroid-resistant rejection episodes in kidney transplant recipients.
Mariat C; Alamartine E; Diab N; de Filippis JP; Laurent B; Berthoux F
Transpl Int; 1998; 11(3):231-6. PubMed ID: 9638854
[TBL] [Abstract][Full Text] [Related]
2. Treatment of steroid-resistant and recurrent acute cardiac transplant rejection with a short course of antibody therapy.
Cantarovich M; Latter DA; Loertscher R
Clin Transplant; 1997 Aug; 11(4):316-21. PubMed ID: 9267721
[TBL] [Abstract][Full Text] [Related]
3. Polyclonal and monoclonal antibodies for treating acute rejection episodes in kidney transplant recipients.
Webster AC; Wu S; Tallapragada K; Park MY; Chapman JR; Carr SJ
Cochrane Database Syst Rev; 2017 Jul; 7(7):CD004756. PubMed ID: 28731207
[TBL] [Abstract][Full Text] [Related]
4. Individualized T cell monitored administration of ATG versus OKT3 in steroid-resistant kidney graft rejection.
Midtvedt K; Fauchald P; Lien B; Hartmann A; Albrechtsen D; Bjerkely BL; Leivestad T; Brekke IB
Clin Transplant; 2003 Feb; 17(1):69-74. PubMed ID: 12588325
[TBL] [Abstract][Full Text] [Related]
5. Polyclonal and monoclonal antibodies for induction therapy in kidney transplant recipients.
Hill P; Cross NB; Barnett AN; Palmer SC; Webster AC
Cochrane Database Syst Rev; 2017 Jan; 1(1):CD004759. PubMed ID: 28073178
[TBL] [Abstract][Full Text] [Related]
6. Evaluation of OKT3 monoclonal antibody and anti-thymocyte globulin in the treatment of steroid-resistant acute allograft rejection in pediatric renal transplants.
Mochon M; Kaiser B; Palmer JA; Polinsky M; Flynn JT; Caputo GC; Baluarte HJ
Pediatr Nephrol; 1993 Jun; 7(3):259-62. PubMed ID: 8518094
[TBL] [Abstract][Full Text] [Related]
7. A randomized prospective trial of prophylactic immunosuppression with ATG-fresenius versus OKT3 after renal transplantation.
Bock HA; Gallati H; Zürcher RM; Bachofen M; Mihatsch MJ; Landmann J; Thiel G
Transplantation; 1995 Mar; 59(6):830-40. PubMed ID: 7701577
[TBL] [Abstract][Full Text] [Related]
8. Antilymphocyte globulin versus OKT3 induction therapy in cadaveric kidney transplantation: a prospective randomized study.
Grino JM; Castelao AM; Serón D; Gonzalez C; Galceran JM; Gil-Vernet S; Andrés E; Mestre M; Torras J; Alsina J
Am J Kidney Dis; 1992 Dec; 20(6):603-10. PubMed ID: 1462990
[TBL] [Abstract][Full Text] [Related]
9. Predicting factors of long-term results of OKT3 therapy for steroid resistant acute rejection following cadaveric renal transplantation.
Rostaing L; Chabannier MH; Modesto A; Rouzaud A; Cisterne JM; Tkaczuk J; Durand D
Am J Nephrol; 1999; 19(6):634-40. PubMed ID: 10592356
[TBL] [Abstract][Full Text] [Related]
10. Half dose of OKT3 is efficient in treatment of steroid-resistant renal allograft rejection.
Midtvedt K; Tafjord AB; Hartmann A; Eide TC; Holdaas H; Nordal KP; Draganov B; Sødal G; Leivestad T; Fauchald P
Transplantation; 1996 Jul; 62(1):38-42. PubMed ID: 8693541
[TBL] [Abstract][Full Text] [Related]
11. Antilymphocyte globulins versus OKT3 as prophylactic treatment in highly sensitized renal transplant recipients.
Vela C; Cristol JP; Chong G; Okamba A; Lorho R; Mion C; Mourad G
Transpl Int; 1994; 7 Suppl 1():S259-62. PubMed ID: 11271219
[TBL] [Abstract][Full Text] [Related]
12. Polyclonal and monoclonal antibodies for treating acute rejection episodes in kidney transplant recipients.
Webster A; Pankhurst T; Rinaldi F; Chapman JR; Craig JC
Cochrane Database Syst Rev; 2006 Apr; (2):CD004756. PubMed ID: 16625610
[TBL] [Abstract][Full Text] [Related]
13. A randomized prospective trial of low-dose OKT3 induction therapy to prevent rejection and minimize side effects in recipients of kidney transplants.
Flechner SM; Goldfarb DA; Fairchild R; Modlin CS; Fisher R; Mastroianni B; Boparai N; O'Malley KJ; Cook DJ; Novick AC
Transplantation; 2000 Jun; 69(11):2374-81. PubMed ID: 10868643
[TBL] [Abstract][Full Text] [Related]
14. Monoclonal antibodies in renal transplantation: a review.
Parlevliet KJ; Schellekens PT
Transpl Int; 1992 Sep; 5(4):234-46. PubMed ID: 1418316
[TBL] [Abstract][Full Text] [Related]
15. A pharmacoeconomic comparison of antithymocyte globulin and muromonab CD3 induction therapy in renal transplant recipients.
Brennan DC; Schnitzler MA; Baty JD; Ceriotti CS; Lowell JA; Shenoy S; Howard TK; Woodward RS
Pharmacoeconomics; 1997 Mar; 11(3):237-45. PubMed ID: 10165313
[TBL] [Abstract][Full Text] [Related]
16. Immediate and long-term results of ATG induction therapy for delayed graft function compared to conventional therapy for immediate graft function.
Lange H; Müller TF; Ebel H; Kuhlmann U; Grebe SO; Heymanns J; Feiber H; Riedmiller H
Transpl Int; 1999; 12(1):2-9. PubMed ID: 10080400
[TBL] [Abstract][Full Text] [Related]
17. [Kidney-pancreas transplantation. Clinical results in 23 consecutive patients].
Maestri M; Krieger N; Kuo P; Dafoe DC; Alfrey EJ
Minerva Chir; 1998 Mar; 53(3):121-8. PubMed ID: 9617106
[TBL] [Abstract][Full Text] [Related]
18. Muromonab CD3: a reappraisal of its pharmacology and use as prophylaxis of solid organ transplant rejection.
Wilde MI; Goa KL
Drugs; 1996 May; 51(5):865-94. PubMed ID: 8861551
[TBL] [Abstract][Full Text] [Related]
19. Single-shot antithymocyte globulin (ATG) induction for pancreas/kidney transplantation: ATG-Fresenius versus Thymoglobulin.
Schulz T; Papapostolou G; Schenker P; Kapischke M
Transplant Proc; 2005 Mar; 37(2):1301-4. PubMed ID: 15848703
[TBL] [Abstract][Full Text] [Related]
20. A prospective randomized study comparing poly-ATG to mono-OKT3 clonal antibodies for the first rejection therapy after kidney transplantation: long-term results.
Baldi A; Malaise J; Mourad M; Squifflet JP
Transplant Proc; 2000 Mar; 32(2):429-31. PubMed ID: 10715467
[No Abstract] [Full Text] [Related]
[Next] [New Search]
